Citigroup lowered shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a neutral rating to a sell rating in a report released on Friday, Marketbeat Ratings reports. Citigroup currently has $25.

In a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump’s inauguration fund, signaling its ...

What initially stands out to me about Hims & Hers is the company's distinct branding and feel of luxury, which is evident on ...

Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.

Citi downgraded telehealth company Hims & Hers Health (NYSE:HIMS) to Sell from Neutral and upgraded value-based care provider agilon health (NYSE:AGL) to Neutral from Sell on Friday as part of its ...

Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have been given a consensus recommendation of “Hold” by the ...

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Analyst Ryan MacDonald of Needham maintained a Buy rating on Hims & Hers Health (HIMS – Research Report), boosting the price target to ...

Ratings for Hims & Hers Health HIMS were provided by 12 analysts in the past three months, showcasing a mix of bullish and ...

Yet Hims & Hers is still up nearly 200% over the past 12 months. The company has made headlines for selling compounded versions of GLP-1 agonists, the popular diabetes and weight loss drugs ...